Search Results for “HIV” – Page 7 – media

The world’s first, created in China! Weekly insulin preparation Novozyme® debuts at CIIE, to be launched at the end of the month

On November 6, at the 7th China International Import Expo (hereinafter referred to as “CIIE”), Novo Nordisk held a press conference and announced that the world’s first weekly insulin formulation, Novozymes® (insulin Efficacy Injection), which was exhibited for the first time at this CIIE, will be commercially launched in China at the end of November 2024 for the treatment of type 2 diabetes in adults, ushering in the era of weekly insulin treatment. Professor Peng Yongde, head of the Department of Endocrinology and Metabolism at the First People’s Hospital affiliated to Shanghai Jiao Tong University School of Medicine, said: “Insulin therapy is still an indispensable and important cornerstone in the diabetes management pathway. As a key component, basal insulin strives to better meet clinical treatment needs to help patients start treatment in a timely manner, improve treatment compliance, increase treatment continuity, and improve patient satisfaction.” Insulin “from day to week” ...
- Source: drugdu
- 56
- November 8, 2024
Kejun Pharmaceuticals Completes B+ Round of Phased Financing

On October 31, Shanghai Kejun Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Kejun Pharmaceutical”) announced the completion of its B+ round of phased financing. This round of financing was led by Guoxin Innovation Equity, and other major investors included Aeon Group and Infinity Capital, and the original investor Honghai Capital also continued to make additional investments. Qidian Capital served as the financial advisor for this round of financing and will continue to provide financing services to Kejun Pharmaceutical in the future. Kejun Pharmaceutical stated that the funds raised from this financing will be used to accelerate the clinical development of CG-0255, a core product in the cardiovascular field. About Kejun Pharmaceutical Kejun Pharmaceutical was established in Zhangjiang, Shanghai in 2018, focusing on the treatment of cardiovascular and cerebrovascular diseases and antiviral diseases, and focusing on the research and development of small molecules and nucleic acid drugs. At present, Kejun ...
- Source: drugdu
- 52
- November 7, 2024
Two innovative medical devices have been approved for market launch

Recently, the National Medical Products Administration announced the approval of the registration applications for two innovative products, Yabonixi Medical Technology (Suzhou) Co., Ltd.’s “knee joint prosthesis system” and Shanghai Xinwei Medical Technology Co., Ltd.’s “intracranial aneurysm embolization assisted stent”. Yabonixi Medical offers freedom of movement in all aspects Yabonixi Medical is a wholly-owned subsidiary of Jiaoying Medical Equipment (Shanghai) Co., Ltd., dedicated to the research, development, production, and sales of high-end orthopedic medical equipment, minimally invasive surgical medical equipment, and more. Yabonixi Medical was founded by Dr. Yao Jianqing, a leading figure in the international orthopedic field. It is reported that Yao Jianqing is an experienced veteran in the field of medical devices, with 36 years of rich experience in medical device and tissue engineering research and industrialization. He has served as the Global R&D Senior Director and Asia Pacific R&D Senior Director of ZimmerBiomet, a joint company. Yao Jianqing ...
- Source: drugdu
- 57
- November 6, 2024
Another GLP-1 drug king, is it on the way?

Recently, the Q3 financial reports of MNCs have been released one after another, and some are happy and some are sad. When a number of MNCs began to lower their full-year EPS, Amgen’s Q3 financial report earnings gave a high score answer sheet. Among them, Amgen’s total revenue in the third quarter increased by 23%, and its GAAP net earnings per share (EPS) increased by 62% year-on-year, from US$3.22 to US$5.22. What is more imaginative is that with the data catalysis of the new macromolecular weight loss drug AMG133, this macromolecular antibody that goes against the grain and antagonizes GIPR may become Amgen’s next gold mine. According to Amgen’s Q3 2024 financial report, the most significant year-on-year growth is LUMAKRAS (AMG510) – a targeted drug for KRASG12C mutation-positive lung cancer. The sales ceiling of this gene mutation in European and American countries will be much higher than that in Asian ...
- Source: drugdu
- 60
- November 6, 2024
Sonavex announces completion of new round of financing

According to the Medicine Intelligence Data Investment Pattern Database, Sonavex, an innovative ultrasound technology company, recently announced the completion of a $15 million (contract RMB 106 million) Series A-2 financing to support its ultrasound technology. This round of financing has attracted several new investors and received strong participation from existing shareholders and industry veterans. Sonavex is a medical device company located in Baltimore, Maryland, spun off from Johns Hopkins University. Sonavex focuses on developing innovative ultrasound solutions to provide critical visual and quantitative data, improve patient treatment outcomes, and reduce healthcare costs. Medical ultrasound technology is a crucial imaging diagnostic tool in modern medicine, playing a crucial role in clinical diagnosis and treatment. However, there are still some technical limitations in traditional ultrasound technology, such as limited resolution and imaging quality due to factors such as sound wave frequency and probe size; Real time imaging and high frame rate are ...
- Source: drugdu
- 43
- November 5, 2024
Hengrui Medicine’s “2 Category 1 new drugs” approved for clinical trials

Recently, according to the official website of CDE, two Class 1 new drugs of Hengrui Medicine have obtained implicit approval for clinical trials, namely HRS-5632 injection and HRS-6208 capsule. The former is intended to treat lipoprotein disorders, and the latter targets solid tumors. Lipoprotein disorders Lipoprotein disorder refers to the abnormal metabolism of plasma lipoproteins. Studies have shown that it may lead to abnormal transport and distribution of lipids in the blood, thus causing a series of health problems. At present, lipoprotein disorder has been confirmed to be an independent risk factor for atherosclerotic cardiovascular disease (ASCVD), and there is no specific drug to treat it. It is reported that cardiovascular diseases, mainly ASCVD, are the leading cause of death among urban and rural residents in China, accounting for more than 45% of the causes of death. In response to lipoprotein disorder, Hengrui Medicine has deployed a small molecule drug ...
- Source: drugdu
- 56
- November 5, 2024
16 billion yuan! Novartis “runs” to enter the market

Recently, the molecular glue star company Monte Rosa Therapeutics announced that it has reached a global exclusive development and commercialization license agreement with Novartis to advance the development of molecular glue protein degraders targeting VAV1, including the research therapy MRT-6160. Under the terms of the agreement, Novartis agreed to pay Monte Rosa an advance payment of US$150 million. In addition, Monte Rosa is eligible to receive up to US$2.1 billion in development, regulatory and sales milestone payments (US$2.25 billion is approximately RMB 16 billion). Monte Rosa Therapeutics is headquartered in Boston, USA. The company was founded in 2018 and is a biotechnology company focusing on the development of molecular glue drugs. Its core technology platform is the QuEEN platform, which is mainly dedicated to the discovery and development of molecular glue drugs. Under the terms of the agreement, Monte Rosa will continue to be responsible for completing the ongoing Phase ...
- Source: drugdu
- 43
- November 4, 2024
Domestic PD-L1 was approved in the UK for the first time

CStone Pharmaceuticals announced today (October 31) that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved sugemalimab combined with platinum-containing chemotherapy for patients without EGFR sensitive mutations, or without ALK, ROS1, First-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with RET genomic tumor variants. This is the second marketing authorization application approval for sugalimab in overseas markets, following the approval by the European Commission. The approval was mainly based on the results of a multi-center, randomized, double-blind Phase III clinical study – GEMSTONE-302. Sugemalimab combined with chemotherapy can significantly extend the progression-free survival and overall survival of patients with newly treated metastatic NSCLC compared with placebo combined with chemotherapy. The research data has been published in The Lancet Oncology and Nature Cancer, and has been presented in oral and poster presentations at many international academic conferences. CStone Pharmaceuticals has reached a strategic cooperation with ...
- Source: drugdu
- 45
- November 4, 2024
Is the turning point of “Cosmic Pharmaceutical Factory” coming?

In 2022, Pfizer’s annual revenue exceeded $100 billion, making it the world’s largest pharmaceutical company in terms of revenue. However, as the COVID-19 pandemic quickly receded, revenue fell by 41% in 2023, and revenue ranking also dropped from first to fourth. Recently, the well-known radical investment institution Starboard Value invested $1 billion in Pfizer. What changes will this bring to this pharmaceutical giant? In 1849, Charles Pfizer and Charles Erhart founded Pfizer in New York, initially focusing on the production of chemical products. During World War II, Pfizer successfully mass-produced penicillin and launched oxytetracycline, officially entering the pharmaceutical industry. Since then, Pfizer has continued to expand through research and development and mergers and acquisitions, launched blockbuster drugs such as Norvasc and Viagra, and gradually became a leading global pharmaceutical company. Since the 21st century, Pfizer has topped the list of the top 50 pharmaceutical companies in the world (Pharm Exec ...
- Source: drugdu
- 64
- November 2, 2024
Hengrui Medicine plans to be listed on the Hong Kong Stock Exchange?

According to overseas media Bloomberg, Jiangsu Hengrui Medicine Co., Ltd. is considering a second listing in Hong Kong next year. People familiar with the matter said that the company is discussing potential share sales with consultants, which may raise at least US$2 billion (about HK$15.5 billion). This news has attracted widespread attention. In response, Hengrui Medicine said that it “would not comment” on the rumor.Affected by this news, Hengrui Medicine’s stock price has fluctuated significantly, and its current market value is about RMB 300 billion (US$43 billion). In recent years, “A+H” stocks have continued to expand. With the listing of Midea Group on the Hong Kong Stock Exchange on September 17, there are currently 150 companies that have successfully achieved “A+H” dual listings. Among them are many biopharmaceutical companies, including innovative pharmaceutical companies: Innovent Biologics, Fudan Zhangjiang, CanSino Biologics, Rongchang Bio, Junshi Biosciences, BeiGene, etc., traditional pharmaceutical companies: Shanghai Pharmaceuticals, ...
- Source: drugdu
- 62
- October 31, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.